Peritoneal fibrosis intervention.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Kaneko K;Kaneko K; Hamada C; Tomino Y
  • Source:
    Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis [Perit Dial Int] 2007 Jun; Vol. 27 Suppl 2, pp. S82-6.
  • Publication Type:
    Journal Article; Review
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: SAGE Publications Country of Publication: United States NLM ID: 8904033 Publication Model: Print Cited Medium: Print ISSN: 0896-8608 (Print) Linking ISSN: 08968608 NLM ISO Abbreviation: Perit Dial Int Subsets: MEDLINE
    • Publication Information:
      Publication: 2020- : [Thousand Oaks, CA] : SAGE Publications
      Original Publication: New York : Pergamon Press, c1988-
    • Subject Terms:
      Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use ; Fibrosis/*prevention & control ; Peritoneal Dialysis/*adverse effects ; Peritoneum/*pathology ; ortho-Aminobenzoates/*therapeutic use; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Animals ; Biocompatible Materials ; Dialysis Solutions/chemistry ; Epithelial Cells/metabolism ; Epithelial Cells/pathology ; Humans ; Hyaluronic Acid/blood ; Inflammation Mediators/blood ; Peptide Fragments/blood ; Peritoneum/metabolism ; Procollagen/blood ; Risk Factors ; Transforming Growth Factor beta/blood
    • Abstract:
      Peritoneal fibrosis (PF) is invariably observed in patients undergoing long-term peritoneal dialysis (PD). The condition is thought to occur in response to a variety of insults, including bioincompatible dialysates (acidic solution, high glucose, glucose degradation products, or a combination), peritonitis, uremia, and chronic inflammation. Recently, the pathophysiologic mechanisms that contribute to the fibrosing process have been intensively studied. Transforming growth factor-beta has been shown to be a key mediator of PF. Loss of the mesothelial cell layer has been identified in several studies and shown to correlate with submesothelial thickening and vasculopathy. An association has also been identified between increased submesothelial thickness in the peritoneal membrane and increased solute transport, suggesting a relationship between PF and loss of ultrafiltration capacity. Thus, to maintain long-term PD and improve quality of life for patients, it is important to develop interventions for prevention and treatment of PF. Several strategies for peritoneal fibrosis intervention have been reported, including developing biocompatible dialysate, targeting mediators responsible for inflammation and fibrosis, and reconstituting the peritoneum using mesothelial or bone marrow-derived cells. Recent experimental trials in animal models and clinical studies are presented in this review.
    • Number of References:
      38
    • Accession Number:
      0 (Angiotensin-Converting Enzyme Inhibitors)
      0 (Anti-Inflammatory Agents, Non-Steroidal)
      0 (Biocompatible Materials)
      0 (Dialysis Solutions)
      0 (Inflammation Mediators)
      0 (Peptide Fragments)
      0 (Procollagen)
      0 (Transforming Growth Factor beta)
      0 (ortho-Aminobenzoates)
      0 (procollagen Type III-N-terminal peptide)
      9004-61-9 (Hyaluronic Acid)
      HVF50SMY6E (tranilast)
    • Publication Date:
      Date Created: 20071122 Date Completed: 20080124 Latest Revision: 20200109
    • Publication Date:
      20231215
    • Accession Number:
      17556336